Boosting Schizophrenia Cognition with Brain Stimulation

Silas E. — Tue, 13 Jan 2026 10:20:43 +0000

In a groundbreaking randomized sham-controlled study, researchers have unveiled promising advancements in the treatment of schizophrenia, particularly targeting its cognitive and emotional deficits. The study investigates the efficacy of bilateral prefrontal anodal transcranial direct current stimulation (tDCS) combined with high-frequency transcranial random noise stimulation (tRNS) in modulating brain function in individuals diagnosed with schizophrenia. This novel approach harnesses the power of non-invasive brain stimulation to potentially revolutionize therapeutic strategies for a disorder historically resistant to effective cognitive and emotional remediation.

Schizophrenia is a complex psychiatric disorder characterized by a constellation of symptoms, including profound cognitive impairments and emotional dysregulation, which severely impact patients’ quality of life. Conventional pharmacological treatments primarily address positive symptoms such as hallucinations and delusions but often fail to ameliorate cognitive deficits or emotional disturbances. This unmet need has propelled the scientific community to explore cutting-edge neuromodulation techniques that can directly influence brain circuitry responsible for cognitive and affective processes.

The bilateral prefrontal cortex, a hotspot for executive function, decision-making, and emotional regulation, has emerged as a critical target for neuromodulation. Electrical stimulation modalities like tDCS and tRNS can alter cortical excitability and plasticity, thereby reshaping dysfunctional neural networks implicated in schizophrenia. Anodal tDCS involves applying a low-intensity current to enhance neuronal firing rates, while high-frequency tRNS delivers stochastic electrical noise that can potentiate synaptic efficacy through mechanisms akin to stochastic resonance.

In this meticulously designed study, the research team applied bilateral prefrontal anodal tDCS and high-frequency tRNS in individuals diagnosed with schizophrenia, comparing the outcomes with a sham-controlled group that received placebo stimulation. The double-blind setup ensured rigorous control of bias, offering credible and replicable results for assessing the causal influence of these stimulation protocols on cognitive and emotional domains.

Advanced neuropsychological assessments conducted pre- and post-intervention revealed significant enhancements in executive functions, working memory, and cognitive flexibility among the treatment group. These improvements suggest that targeted electrical stimulation can effectively recalibrate dysfunctional prefrontal circuits, whose impaired activity is strongly correlated with cognitive deficits observed in schizophrenia. Notably, the modulation of cortico-subcortical pathways via bilateral stimulation seemed instrumental in fostering this neurocognitive recovery.

Beyond cognition, the study illuminates substantial amelioration in emotional processing and affective regulation. Patients receiving bilateral tDCS and tRNS interventions exhibited reductions in negative symptoms such as anhedonia and blunted affect, which frequently go untreated with standard therapies. The findings intimate that enhanced prefrontal excitation may restore top-down regulatory control over limbic structures, thereby normalizing emotional responsiveness and improving social functioning.

The mechanistic underpinnings of these neuromodulatory effects derive from the interaction of local cortical excitability enhancements with widespread network synchronization. High-frequency tRNS, in particular, is posited to induce synaptic noise that facilitates neural adaptation and plasticity by modulating ion channel kinetics and increasing the signal-to-noise ratio of neuronal firing patterns. When coupled with anodal tDCS, this synergistic approach may boost long-term potentiation-like phenomena, counteracting synaptic deficits linked to schizophrenia.

Importantly, the intervention protocol demonstrated excellent tolerability and safety, with minimal side effects reported, affirming the feasibility of repeated administrations in clinical settings. This profile is critical for translational applications, considering the chronic and debilitating nature of schizophrenia and the necessity for sustainable treatment modalities that do not exacerbate somatic health issues.

The implications of this research extend beyond immediate therapeutic gains, providing a framework for integrating neurostimulation with cognitive rehabilitation strategies. By enhancing neural plasticity, bilateral prefrontal tDCS and high-frequency tRNS may prime patients for more effective engagement in cognitive-behavioral therapies, unlocking synergies that optimize long-term functional recovery.

Moreover, the study rigorously explores individual variability in responses to stimulation, highlighting factors such as baseline cortical excitability and neurochemical milieu that may modulate treatment efficacy. This personalized medicine perspective is crucial for tailoring intervention protocols to maximize benefits and minimize non-responders in heterogeneous schizophrenia populations.

The findings also incite intriguing questions regarding the neurodevelopmental trajectories of schizophrenia and the potential of early intervention with neuromodulation to alter disease progression. Future longitudinal studies could elucidate whether such technologies can preemptively buffer cognitive decline during prodromal phases or enhance resilience in at-risk populations.

While the research presents compelling evidence of the cognitive and emotional benefits of bilateral prefrontal tDCS and high-frequency tRNS, it also underscores the necessity for further elucidation of optimal stimulation parameters, including current intensity, session frequency, and electrode montage. Refining these variables will be instrumental in maximizing the therapeutic window and individualizing protocols.

Additionally, the integration of neuroimaging techniques, such as functional MRI and EEG, could offer valuable insights into the network dynamics altered by stimulation, fostering a mechanistic understanding that bridges behavioral outcomes with underlying neurophysiology. Such multi-modal approaches will be invaluable for validating biomarkers of responsiveness and guiding clinical decision-making.

In sum, this pioneering investigation charts a promising course for the use of non-invasive brain stimulation in addressing the debilitating cognitive and emotional challenges of schizophrenia. By leveraging bilateral prefrontal anodal tDCS in concert with high-frequency tRNS, the study heralds a new era of targeted, neurobiologically informed interventions that could substantially improve patient outcomes and quality of life.

As mental health research continues to evolve, these advancements underscore the critical role of interdisciplinary collaboration, uniting neurophysiology, psychiatry, and engineering in devising innovative solutions for complex psychiatric disorders. The translational potential of these findings fuels optimism for the development of personalized, precision therapies that transcend symptom management to foster true neurological rehabilitation.

Ultimately, the integration of neuromodulatory techniques like tDCS and tRNS offers a transformative avenue not only for schizophrenia but also for a range of neuropsychiatric conditions characterized by cognitive and emotional dysregulation. This study lays the groundwork for expansive future research, poised to unravel the complexities of brain-behavior relationships and pioneer novel therapeutic paradigms.

Subject of Research: Cognitive and emotional effects of bilateral prefrontal anodal tDCS and high-frequency tRNS in schizophrenia

Article Title: Cognitive and emotional effects of bilateral prefrontal anodal tDCS and high-frequency tRNS in schizophrenia: a randomized sham-controlled study

Article References:
Jafari, E., Moghadamzadeh, A., Vaziri, Z. et al. Cognitive and emotional effects of bilateral prefrontal anodal tDCS and high-frequency tRNS in schizophrenia: a randomized sham-controlled study. Schizophr (2026). https://doi.org/10.1038/s41537-025-00720-z

Image Credits: AI Generated

CBT and tDCS Improve Social Anxiety, Depression

Silas E. — Tue, 29 Apr 2025 18:58:27 +0000

Efficacy of CBT, intensified tDCS and their combination for reducing clinical symptoms and improving quality of life in social anxiety disorder with comorbid depression: a randomized controlled trial

BMC Psychiatry

volume 25, Article number: 438 (2025)
Cite this article

Background/aim

Social anxiety disorder (SAD) is a common and disabling psychiatric disorder. It is generally treated with medication and psychotherapy such as cognitive-behavioral therapy (CBT). Due to the involvement of cortical and subcortical areas in the pathophysiology of SAD, non-invasive brain stimulation techniques such as transcranial Direct Current Stimulation (tDCS) are potential adjunctive treatment options for SAD. This study aims to assess comparable efficacy of CBT, intensified tDCS, and combined CBT/tDCS on clinical symptoms and quality of life of patients with SAD and comorbid depression.

Methods

In this randomized controlled trial, 37 adults with SAD and comorbid depressive disorder were assigned into three groups: (1) CBT + active tDCS (n = 13), (2) active tDCS alone (n = 12), and (3) CBT + sham tDCS (n = 12). SAD symptoms, depressive states, quality of life and trait worry were assessed with the Liebowitz Social Anxiety Scale, Beck’s Depression Inventory, QOL questionnaire (WHOQOL-BREF), and the Penn State Worry Questionnaire respectively. The active tDCS was an intensified stimulation protocol (20 min, twice-daily sessions with 20 min intervals, 5 consecutive days) and was applied over the left dorsolateral prefrontal cortex (F3) and medial prefrontal cortex (Fpz). The CBT was provided individually based on the exposure technique at 12–20 sessions, twice a week. All clinical measures were assessed at baseline, after the intervention, and at 3-month follow-up.

Results

SAD symptoms significantly decreased after intervention and follow-up in all groups, with no significant differences between them. However, CBT + tDCS resulted in a numerically larger symptom reduction, significantly exceeding CBT + sham tDCS on the fear scale. Depressive states and trait worry significantly improved in all groups post-intervention and at the 3-month follow-up, with no between-group differences. Quality of life (total scores, physical, and psychological domains) significantly improved after the and at the 3-month follow-up only in the CBT + tDCS and tDCS-alone groups with no between-group differences.

Conclusion

Psychotherapeutic interventions with CBT, intensified tDCS targeting the prefrontal cortex, and the combined CBT-tDCS are effective for alleviating primary and secondary clinical symptoms in individuals with SAD. The combined CBT-tDCS intervention showed superior efficacy in reducing the primary symptoms of SAD.

Trial registration ID

IRCT20220421054607N1, registration date: 19/05/2022, available at: https://irct.behdasht.gov.ir/trial/63119.

Amiri Sararudi, P., Khakpour, M.S., Kazemi, M. et al. Efficacy of CBT, intensified tDCS and their combination for reducing clinical symptoms and improving quality of life in social anxiety disorder with comorbid depression: a randomized controlled trial.
BMC Psychiatry 25, 438 (2025). https://doi.org/10.1186/s12888-025-06866-5

https://doi.org/10.1186/s12888-025-06866-5

transcranial Direct Current Stimulation benefits – Science